Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04592653
Title A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alkermes, Inc.

triple-receptor negative breast cancer

ovarian cancer

Advanced Solid Tumor

skin melanoma

colorectal cancer

renal cell carcinoma


ALKS 4230 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.